



IN THE COMPETITION
APPEAL TRIBUNAL

Case Nos: 1432/1/12/22
1434/1/12/22
1438/1/12/22
1439/1/12/22

BETWEEN:

- (1) ADVANZ PHARMA CORP. LIMITED & OTHERS
(2) CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER
LIMITED & OTHERS
(3) LEXON (UK) LIMITED & ANOTHER
(4) ALLIANCE PHARMACEUTICALS LIMITED & ANOTHER

Appellants

- v -

COMPETITION AND MARKETS AUTHORITY

Respondent

ORDER

UPON the application by the Appellants made on 20 June 2022 for case management directions in relation to all appeals against the decision of the Respondent of 3 February 2022 in Case 50511-2 Prochlorperazine

AND UPON reading the correspondence from the parties with respect to the Application

AND HAVING REGARD TO rules 17 to 20 of the Competition Appeal Tribunal Rules 2015 (the “Tribunal Rules”)

IT IS ORDERED THAT:

Forum

1. Pursuant to Rule 18 of the Tribunal Rules, the proceedings shall be treated as proceedings in England and Wales.

Consolidation

2. The appeals shall be case managed together.
3. The evidence in each appeal shall stand as evidence in other appeals.

Replies

4. If so advised, the Appellants may each file and serve Replies, together with any supporting evidence, by 4 p.m. on 26 August 2022.

General

5. Liberty to apply.

The Honourable Lord Ericht
Chair of the Competition Appeal Tribunal

Made: 4 July 2022
Drawn: 4 July 2022